The promising role of monoclonal antibodies for immunotherapy of the HIV-associated cancer,non-Hodgkin lymphoma |
| |
| Authors: | Omid Rezahosseini Sara Hanaei Mehdi Hamadani Mahsa Keshavarz-Fathi |
| |
| Affiliation: | 1. Cancer Immunology Project (CIP), Universal Scientific Education and Research Network (USERN), Tehran, Iran;2. Department of Infectious and Tropical diseases, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran;3. Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran;4. School of Medicine, Tehran University of Medical Sciences, Tehran, Iran;5. Division of Hematology &6. Oncology, Medical College of ?Wisconsin, Milwaukee, WI, USA;7. Cancer Immunology Project (CIP), Universal Scientific Education and Research Network (USERN), Milwaukee, WI, USA;8. Students' Scientific Research Center, Tehran University of Medical Sciences, Tehran, Iran |
| |
| Abstract: | Association between HIV/AIDS and some of the cancers such as lymphomais is well known. Relative risk for developing non-Hodgkin lymphoma (NHL) increases 60–200 folds in HIV-infected individuals. Diffuse large B cell lymphoma (DLBCL), primary effusion lymphoma (PEL), Burkitt's lymphoma (BL) and Plasmablastic Lymphoma (PBL) are among the most frequent subtypes. During the last century, scientists found that the immune system could potentially detect and destroy cancer cells. Therefore, they started a new field of study, which is named immunotherapy. There are different immunotherapeutic methods, among which therapeutic antibodies, such as Brentuximabvedotin (Adcetris), Ibritumomabtiuxetan (Zevalin) and rituximab (Rituxan), used for treatment of NHLs showed promising results. In this article, we will review the immunotherapeutic option, monoclonal antibodies, for treatment of HIV-associated NHLs as well as their recent clinical status. We will also discuss the selective monoclonal antibody for each subtype of NHLs. |
| |
| Keywords: | HIV-associated non-Hodgkin lymphoma human immunodeficiency virus immunotherapy monoclonal antibodies neoplasm rituximab |
|
|
